Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
InPACT: International Penile Advanced Cancer Trial
NCT02305654Phase 3Active, not recruiting
- Sponsor
- The Institute of Cancer Research
- Start
- May 2017
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of Paclitaxel Micelles for Injection, ifosfamide and Cisplatin micelle injection (HA132) in squamous cell carcinoma of the penis (5 arms), sponsored by The Institute of Cancer Research. Primary endpoint: Overall survival at 5 years. Started May 2017; status: active, not recruiting.
02
Drugs
Paclitaxel Micelles for InjectionifosfamideCisplatin micelle injection (HA132)
03
Conditions
squamous cell carcinoma of the penis
Beyond the preview
Go deeper on NCT02305654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02305654.